Barry Investment Advisors LLC Raises Stock Holdings in GSK plc (NYSE:GSK)

Barry Investment Advisors LLC lifted its stake in shares of GSK plc (NYSE:GSK) by 9.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,461 shares of the pharmaceutical company’s stock after purchasing an additional 1,741 shares during the quarter. Barry Investment Advisors LLC’s holdings in GSK were worth $692,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the stock. AQR Capital Management LLC grew its holdings in GSK by 103.4% in the second quarter. AQR Capital Management LLC now owns 26,363 shares of the pharmaceutical company’s stock valued at $1,015,000 after purchasing an additional 13,403 shares during the last quarter. Creative Planning lifted its position in GSK by 4.8% during the second quarter. Creative Planning now owns 203,246 shares of the pharmaceutical company’s stock worth $7,825,000 after buying an additional 9,322 shares during the period. NewEdge Advisors LLC raised its holdings in shares of GSK by 61.9% in the 2nd quarter. NewEdge Advisors LLC now owns 70,048 shares of the pharmaceutical company’s stock worth $2,697,000 after purchasing an additional 26,793 shares during the period. New Wave Wealth Advisors LLC purchased a new position in shares of GSK in the 2nd quarter worth about $357,000. Finally, Sanctuary Advisors LLC purchased a new position in shares of GSK in the 2nd quarter worth about $11,181,000. Hedge funds and other institutional investors own 15.74% of the company’s stock.

GSK Stock Down 1.1 %

Shares of GSK opened at $35.12 on Wednesday. The firm has a market capitalization of $72.78 billion, a price-to-earnings ratio of 22.80, a PEG ratio of 1.31 and a beta of 0.63. The company has a debt-to-equity ratio of 0.98, a quick ratio of 0.53 and a current ratio of 0.81. The business’s fifty day moving average price is $33.94 and its two-hundred day moving average price is $37.78. GSK plc has a 52 week low of $31.72 and a 52 week high of $45.92.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on GSK shares. StockNews.com downgraded GSK from a “strong-buy” rating to a “buy” rating in a report on Tuesday, January 21st. Guggenheim downgraded GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. Deutsche Bank Aktiengesellschaft downgraded GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Finally, Jefferies Financial Group downgraded GSK from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $53.00 to $39.50 in a research note on Tuesday, November 12th. Six investment analysts have rated the stock with a hold rating, one has assigned a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.